The Private Equity and Public M&A teams advised Novo Holdings in a definitive agreement with Gurnet Point Capital to acquire Paratek Pharmaceuticals (NASDAQ: PRTK). The transaction is valued at approximately $462 million, including the assumption of debt and assuming full payment of a contingent value right.
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation.
Gurnet Point is a leading healthcare fund that invests in de-risked life sciences companies.
Paratek Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats.
For more details, please read the press release.